Abstract
The human placenta produces hematopoietic growth factors including colony stimulating factor-1 (CSF-1). We have previously demonstrated Interleukin-1 beta (IL-1 beta) production by decidualized endometrium during pregnancy. Since IL-1 beta stimulates CSF-1 production in a variety of mesenchymal cell types including second trimester villous core mesenchymal cells, the present study was designed to determine if IL-1 beta could also regulate CSF-1 production in term placental explants in vitro. Placental villous explants from normal term placentas (n = 5) were cultured with or without recombinant human IL-1 beta. A dose response relationship between increased added IL-1 beta and increased CSF-1 production as measured by enzyme-linked immunosorbent assay was observed with 1 ng/mL IL-1 beta being the lowest dose to significantly increase CSF-1 production (P < 0.01). In time course experiments, 10 ng/mL maximally induced CSF-1 messenger RNA expression 2.7 fold (P < 0.005) compared to controls at 8 h of culture as determined by dot blot analysis. Production rates of CSF-1 were linear up to 24 h at which time IL-1 beta (10 ng/mL)-treated samples had 1.7-fold higher levels of CSF-1 in the media than nontreated controls (8.38 ng/gm tissue vs. 4.94 ng/gm tissue, P < 0.01). These results demonstrate that IL-1 beta can regulate placental CSF-1 production in vitro and suggest that maternal decidual IL-1 beta may regulate placental CSF-1 production in vivo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: The Journal of clinical endocrinology and metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.